Bristol-Myers Squibb Company (BMY) : 5 brokerage houses believe that Bristol-Myers Squibb Company (BMY) is a Strong Buy at current levels. 10 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Bristol-Myers Squibb Company (BMY). Zacks Investment Research suggests a Hold with a rank of 3. 2 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 17 Wall Street Analysts endorse the stock as a Hold with a rating of 2.65.
Bristol-Myers Squibb Company (BMY) : 13 investment research analysts covering Bristol-Myers Squibb Company (BMY) have an average price target of $66.69 for the near short term. The highest target price given by the Brokerage Firm to the stock is $100 and the lowest target is $48 for the short term. Analysts expect the variance to be within $13.13 of the average price.
Also, Equity Analysts at the Barclays maintains the rating on Bristol-Myers Squibb Company (NYSE:BMY). The brokerage firm has issued a Equal-weight rating on the shares. The Analysts at the ratings agency lowers the price target from $75 per share to $65 per share. The rating by the firm was issued on September 9, 2016.
Bristol-Myers Squibb Company (NYSE:BMY): After opening at $55.35, the stock dipped to an intraday low of $55.27 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $56.34 and the buying power remained strong till the end. The stock closed at $55.97 for the day, a gain of 1.34% for the day session. The total traded volume was 9,844,567. The stocks close on the previous trading day was $55.23.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.